Objective: In-stent restenosis is a recognized complication of carotid angioplasty and stenting (CAS), and it is associated with an increased risk of stroke. Few case series have reported outcomes separately following carotid endarterectomy (CEA) and CAS for the treatment of in-stent restenosis. In this study, we perform an evaluation of redo-CAS vs CEA in a large contemporary cohort of patients who underwent prior ipsilateral CAS.
The utilization of carotid artery stenting (CAS) in the United States has increased over the years. 1, 2 In the wake of results from the Carotid Revascularization Endarterectomy vs Stenting Trial that revealed noninferiority between primary CAS and primary carotid endarterectomy (CEA) with respect to the composite perioperative outcome, 3 the identification of subsets of patients in which one treatment might outperform the other has gained new focus. One such category is patients with in-stent restenosis (ISR) after primary CAS.
Restenosis remains an important drawback of intravascular stents, and myointimal hyperplasia has been identified as the major mechanism of this occurrence. 4 The incidence of ISR in the coronary arteries ranges from 20% to 50%; however, this complication occurs less frequently in the carotid arteries for reasons yet to be fully understood. 5 In the landmark CREST trial, 6 the incidence of restenosis (>70%) after CAS and CEA were similar: 6% vs 6.3% at 2 years. Results from other studies range from 1.7% to 21% with wide variation in follow-up and threshold for restenosis on imaging. [7] [8] [9] [10] [11] [12] [13] Restenosis was also associated with a four-fold increase in the risk of stroke in the CREST trial. 6 Thus, hemodynamically significant ISR poses a treatment challenge especially in the presence of symptoms or contralateral disease. The comparative safety and effectiveness of redo-CAS vs CEA for the treatment of ISR is relatively understudied. Prior studies have been based on small samples of patients drawn from single institutions, thus, limiting the generalizability of their findings. The objective of this study is to examine 30-day postoperative and 1-year outcomes after redo-CAS vs CEA for the treatment of ISR in a contemporary and nationally representative cohort of patients. We will also identify predictors of adverse outcomes and targets for improvement.
METHODS
We performed a retrospective analysis of all patients in the Vascular Quality Initiative (VQI) who underwent CEA or CAS between January 1, 2003, and April 30, 2016, after a prior ipsilateral CAS. The VQI is a prospectively maintained database approved by the Society for Vascular Surgery. It contains patient-and procedurespecific data from multiple sites across all regions of the United States and incorporates data on mortality from the social security death index. At the end of the study period, there were over 370 hospitals and 2800 participating physicians in the VQI. Details of the data collection and validation process have been published previously. 14 The current study was approved by the VQI Research Advisory Committee, and the Johns Hopkins Institutional Review Board waived the need for individual patient consent under the provisions for deidentified human subject and quality improvement research.
Patients who underwent CEA or CAS after ipsilateral CAS were identified directly from variables recorded in the VQI database. The relevant patient-and procedurerelated data assessed are listed in Table I . Symptomatic status was defined as the occurrence of ipsilateral stroke, transient ischemic attack, or amaurosis fugax within 6 months prior to treatment. The interval between symptom and treatment were also examined. Degree of stenosis was the most severe stenosis obtained from duplex, magnetic resonance angiogram, computed tomography angiogram, or arteriogram. The total number of restenotic cases treated by each surgeon/interventionist was computed as a marker for surgeon experience. Operators were subsequently grouped into quartiles of case volume. Postoperative outcomes (30 day) were ipsilateral stroke, myocardial infarction (MI), death, and composite of stroke/death, stroke/death/MI. One-year outcomes were stroke, death, and the composite of stroke/death. Stroke was defined as the clinical occurrence of minor or major cortical or ocular stroke after surgery/intervention. MI was a clinical or electrocardiogram-confirmed diagnosis or an elevation in troponin. Complications examined were cranial nerve injury, wound infection, access site complications including hematoma or arterial occlusion and procedure related arrhythmia.
Statistical methods. Descriptive analyses of the study groups were performed using c 2 and Student t-tests as appropriate. Univariable and multivariable logistic We performed sensitivity analyses comparing characteristics and outcomes of patients with complete follow-up data at 30 days, 6 months, and 1 year to assess for selection bias because of loss to follow-up. We also performed cluster analyses using unique center identification numbers to assess for the potential impact institutional differences might have on outcomes. All analyses were performed using Stata v 14.1 statistical software (StataCorp, College Station, Texas), and statistical significance was accepted at P value of <.05.
RESULTS
Patient characteristics. There were 645 carotid interventions performed between January 1, 2003, and April 30, 2016, in patients with a prior ipsilateral CAS in the VQI database. Of these, 511 (79%) were redo-CAS, whereas 134 (21%) were CEA. The CAS and CEA cohorts were similar about their age (mean, both 69 years; P ¼ .64), female sex (CAS, 62%; CEA, 59%; P ¼ .60) and racial (Caucasian CAS, 93%; CEA, 95%; P ¼ .17) compositions (Table I) . Comparing CAS vs CEA, the prevalence of hypertension (91% vs 95%; P ¼ .20), coronary artery disease (33 vs 39%; P ¼ .20), and active tobacco use (both 31%; P ¼ .87) were similar between the groups. However, more American Society of Anesthesiologists (ASA) class IV patients underwent CEA vs CAS (31% vs 14%; P < .001). Secondary revascularization was performed most commonly in asymptomatic patients (both 66%; P ¼ .87) for stenosis greater than 80% (60% vs 48%; P ¼ .09).
By augmenting information at patient encounters with data from the social security death index, complete follow-up was achieved for mortality. Assessment for the occurrence of stroke was achieved for 45% at 6 months (CEA, 40%; CAS, 46%; P ¼ .21) and 34% (CEA, 30%; CAS, 35%; P ¼.30) at 1 year. The mean follow-up duration for patients followed up beyond 30 days was 369 (standard deviation, 120; median, 371, interquartile range, 309-447) days for CEA and 354 (standard deviation, 176; median, 367; interquartile range, 288-422) days for CAS (P ¼ .54). The characteristics of patients undergoing redo-CEA vs CAS patients with complete follow-up data at 30-days, 6 months, and 1 year were similar, thus, minimizing the potential for selection bias because of differential loss to follow-up (Table II) . The sensitivity analyses showed no significant difference in results obtained from the subcohorts of patients with complete follow-up at 6 months and 1 year compared with the overall cohort. Herein, we present results from the complete case analyses.
Thirty-day postoperative outcomes. Overall, nine (1.4%) patients suffered ipsilateral stroke within 30 days of the procedure. Of these, two (1.5%) occurred following CEA, whereas seven (1.4%) occurred following CAS (P ¼ .91). For asymptomatic patients, no perioperative stroke occurred within 30 days of CEA, whereas one (0.3%) stroke occurred after redo-CAS (P ¼ .61). For symptomatic patients, two (4.4%) strokes for CEA and six (3.5%) for redo-CAS occurred within 30 days of the procedure (P ¼ .79; Table III) . Absolute, 30-day mortality was significantly higher after CEA compared with CAS (3.7% vs 0.9%; P ¼ .022). However, MI (2.3% vs 1.2%; P ¼ .35), and the composite of stroke/death (4.5% vs 1.9%; P ¼ .09) and stroke/death/MI (5.2% vs 2.7%; P ¼ .15) rates were statistically similar between the treatment groups (Table III) . No wound infection was reported following CEA, whereas cranial nerve injury occurred in 3% of these cases. Technical failure and access site complications occurred in 0.6% and 2.7% of the redo-CAS cases, respectively. The incidence of procedure related arrhythmias was 0.8% for CEA and 1% for CAS (P ¼ .81).
Reperfusion symptoms did not occur after CEA in contrast to 0.6% of CAS cases (P ¼ .38).
The multivariable logistic regression analyses showed that there was no significant difference in the odds of perioperative stroke following CEA compared with CAS (odds ratio [ (Table VI) . One-year outcomes. Overall, there were 12 (1.9%) ipsilateral stroke events over the study period. Of these, two (1.5%) occurred following CEA, and 10 (2%) occurred after CAS (P ¼ .73). Absolute ipsilateral stroke rate was 0.7% (CEA, 0; CAS, 0.9%; P ¼ .38) for asymptomatic patients and 4.2% (CEA, 4.4%; CAS, 4.1%; P ¼ .94) for symptomatic patients. Stroke estimates at 1 year obtained from the Kaplan-Meier analyses were 2.9% (95% CI, 0.7-11.1) for CEA vs 3.9% (95% CI, 2.1-7.5) following CAS (log-rank, P ¼ .80). The multivariable Cox regression analyses showed that there was no significant difference in freedom from stroke for CEA compared with CAS (adjusted hazard ratio [aHR], 0.60; 95% CI, 0.13-2.85; P ¼ .52; Table VII ). Long-term stroke was higher for symptomatic patients compared with asymptomatic patients (aHR, 4.3; 95% CI, 1.14-16.6; P ¼ .03).
Absolute all-cause mortality was 10.2% (CEA, 8.2%; CAS, 10.8%; P ¼ .39) over the entire study period. The KaplanMeier estimates of mortality at 1 year were 7% (95% CI, 3.7-13.0) following CEA vs 6.5% (95% CI, 4.6-9.2) following CAS (log-rank, P ¼ .55). Per symptomatic strata, 1-year mortality estimates from Kaplan-Meier for CEA vs CAS were 5.9% (95% CI, 2.5-13.7) vs 6% (3.8-9.4) for asymptomatic patients (log-rank, P ¼ .69) and 9% (95% CI, 3.5-22.2) vs 7.6% (4.4-13.0) for symptomatic patients (log-rank, P ¼ .60). The Cox regression analyses showed similar mortality in the long term for CEA compared with CAS (aHR, 0.83; 95% CI, 0.42-1.65; P ¼ .60). Long-term survival was similar between symptomatic and asymptomatic patients (aHR, 1.27; 95% CI, 0.74-2.17; P ¼ .38).
The absolute stroke/death rate over the study period was 12.0% (CEA, 10.5%; CAS, 12.4%; P ¼ .56). Unadjusted Kaplan-Meier estimates of stroke/death at 1 year was 8.6% (95% CI, 4.9-15.0) following CEA vs 8.0% (95% CI, 5.8-10.9) following CAS (log-rank, P ¼ .76). Considering symptomatic status, Kaplan-Meier estimates of stroke/ death at 1 year for CEA vs CAS were 7.3% (95% CI, 3.3-5.5) vs 7% (4.6-10.6) for asymptomatic patients (Fig 1) and 11 .1% (95% CI, 4.8-24.7) vs 10.1% (6.3-16.0) for symptomatic patients (Fig 2) . There was no difference 
DISCUSSION
In this contemporary cohort of patients with restenosis following prior ipsilateral CAS, the majority of patients underwent CAS compared with CEA (79% vs 21%) for the treatment of ISR. There was no significant difference in the adjusted risk of stroke, death, or the composite of stroke/death comparing both treatments at 30 days and at 1 year. A few existing studies have reported results separately for redo-CAS 11,15-17 and CEA in patients who Freedom from stroke/death in asymptomatic patients for redo-carotid angioplasty and stenting (CAS) vs carotid endarterectomy (CEA) in patients with prior ipsilateral CAS. This figure shows that in asymptomatic patients with prior CAS who develop restenosis, post reintervention stroke-free survival is not statistically different between redo-CAS and CEA. Standard error for both treatments was less than 10%.
Fig 2.
Freedom from stroke/death in symptomatic patients for redo-carotid angioplasty and stenting (CAS) vs carotid endarterectomy (CEA) in patients with prior ipsilateral CAS. This figure shows that in symptomatic patients with prior CAS who develop restenosis, post reintervention stroke-free survival is not statistically different between redo-CAS and CEA. Standard error for both treatments was less than 10%.
underwent prior ipsilateral CAS. [18] [19] [20] Notably, these studies examined 10 patients or fewer. To our knowledge, this is the first study to perform a direct comparison of perioperative and long-term outcomes following redo-CAS and CEA for the treatment of ISR in a relatively large sample of patients using survival analytic methods. In their evaluation of 10 patients treated with redo-CAS, Reimers et al 17 reported no strokes or death within 17 months of redo-CAS in contrast to stroke incidence of 25% reported by Willfort-Ehringer et al 15 in their assessment of 8 redo-CAS patients. Following operative treatment of ISR, de Borst et al 19 reported no strokes at 13 months of follow-up in four patients. Similarly, no events were recorded in case reports of CEA after ipsilateral CAS. 18, 20 The significantly larger number of patients and multi-institutional nature of the data in the current study provides a more valid and representative estimate of outcomes following these treatments. We acknowledge the efforts of the preceding authors in documenting outcomes for this understudied population of patients. Similar to the proportion of asymptomatic patients in the general and high-risk population of patients who underwent treatment for de novo carotid stenosis, the majority (66%) of patients who underwent treatment for ISR in this study were asymptomatic. [21] [22] [23] [24] The high proportion of asymptomatic patients in this study was largely driven by severity of ipsilateral stenosis and contralateral occlusion. Over 80% of these patients had moderate (>60%), 57% had severe (>80%) ipsilateral stenosis, and 14% had contralateral occlusions. The threshold for treatment of asymptomatic patients in the current study is higher than that reported from a systematic review of 34 studies that showed only 22% of patients treated for ISR were symptomatic compared to 34% in the current study. 25 Follow-up post primary CAS and the cut-offs for the definition of ISR on imaging often attract controversy. At the moment, a consensus is lacking on the parameters for uniform reporting of ISR on duplex ultrasound scan. Understandably, the stent-arterial wall complex differs significantly from native arteries in compliance and other hemodynamic characteristics. Different thresholds of peak systolic velocity yield variations in definition of ISR for therapeutic purposes and several duplex ultrasound grading criteria have been recommended by different authors. 6, 26, 27 The guidelines of the Society for Vascular Surgery indicate that suspicions of ISR on duplex should be confirmed using digital subtraction angiography prior to treatment. 28 The management of patients with ISR exemplifies the delicate balance between the need to intervene to prevent further cerebrovascular compromise and cautious conservative management. The precise identification of the point at which intervention is required is key. This is typically based on the constellation of factors including symptomatic status, the etiology and degree of ipsilateral stenosis, and contralateral disease. In this era of evidence-based practice, an official recommendation of the Society for Vascular Surgery on the treatment of ISR based on these factors is needed; as such a position does not currently exist. We believe the decisions to treat patients with ISR as recorded in this national database were based on the best clinical judgment of vascular surgeon across the United States supported with evidence on imaging. Nonetheless, residual concern exists about the treatment of patients solely on the basis of degree of stenosis; in the absence of symptoms or significant contralateral disease. Although institutional differences in the threshold for revascularization might affect the decision to offer intervention/surgery to individual patients, it is unlikely that these differences will affect the outcomes of intervention/surgery. Not surprisingly, the clustered analyses did not reveal any difference in outcomes.
An understanding of the progression of restenotic disease might be useful in guiding follow-up and intervention for ISR. However, there is significant variability in the current literature. In their 20-month duplex ultrasound scan follow-up study, Leger et al 29 showed progression from moderate to severe ISR in 75% of cases, thus, warranting treatment. In contrast, WillfortEhringer et al 30 showed no progression in neo-intimal hyperplasia of ISR beyond 1 year postprimary CAS, and some regression in patients treated primarily with selfexpanding carotid stents because of positive arterial remodeling. 30, 31 In this study, we do not have the time interval between the initial CAS and restenosis. Thus, we are unable to ascertain which lesions are due to neointimal hyperplasia. Some authors also recommend early consideration of surgical management in patients with calcified lesions that might interfere with stent expansion. 30 These conflicting results and the small number of patients studied leave room for larger studies on ISR progression and the extent to which medical management alters the clinical course as has been done for patients with de novo carotid disease. 32 Angioplasty alone was found to be inferior to angioplasty and stenting in the Carotid and Vertebral Artery Transluminal Angioplasty Study of de novo carotid stenosis. 33 In practice, patients with ISR are often treated with balloon angioplasty alone, and satisfactory results have been reported in some case series. 9, 12, 13, 16 In view of the differences between de novo and restenotic lesions and unique conditions imposed by indwelling stents, objective assessments of large sample of patients are needed to validate and further document the benefit of angioplasty alone for the treatment of ISR. It is possible that some of the patients in the current study failed prior intervention with angioplasty alone. We do not have information on the number and timing of prior angioplasties, hence, we are unable to ascertain the impact they might have on outcomes of subsequent CAS or CEA. The current analysis does not consider factors such as balloon and stent type and size that might contribute to outcomes for CAS but have a limited value in a comparison of CAS vs CEA. Following the decision to revascularize a patient with ISR, nonsignificant difference in outcomes for CEA vs redo-CAS from the current study place emphasis on identification of targets for improvement for either treatment. Symptomatic status did not predict 30-day postoperative stroke/death following CEA possibly because of the relatively small number of patients in this subcohort. In contrast, this characteristic was associated with a 13-fold increase in risk for patients who underwent redo-CAS. The risk of stroke/death was 18-fold greater following CEA (OR, 17.98; 95% CI, 1.22-264.0; P ¼ .035) and 10-fold greater following redo-CAS (OR, 10.02; 95% CI, 1.35-74.2; P ¼ .024) for patients preoperatively classified as having severe systemic disease that is a constant threat to life (ASA class IV) compared with patients with nonincapacitating systemic disease (ASA class III). This finding is similar to that for patients who underwent redo-CEA in a national cohort and questions the value of ISR revascularization in very sick asymptomatic patients. 34 There were significantly more patients with ASA class IV in the CEA group (31% vs 14%; P < .001), which could explain the higher absolute mortality in this group (3.7% vs 0.9%; P ¼ .022). The greater proportion (60%) of patients in ASA class IV were treated for asymptomatic disease, and this class of patients was associated with higher odds of stroke/death as previously stated. Thus, we recommend avoidance of CEA in sick asymptomatic patients with ISR. Prior studies 6, 35 have implicated diabetes mellitus and smoking as risk factors for ISR, and these patient factors negatively influenced outcomes of treatment of ISR in the current study. The current study revealed a 12-fold increase associated with diabetes and a nine-fold increase associated with active smoking in odds of stroke/death within 30 days (Table VI) . Notably, there was no significant difference in the prevalence of these predictors between patients with follow-up at 30 days and patients with longer term follow-up. Consequently, aggressive management of diabetes mellitus and smoking cessation remain potent targets for outcomes improvement. The use of beta blockers had no added benefit for these patients in contrast to findings in patients with de novo disease. 36 This study has shown that redo-CAS and CEA after prior CAS carries significant risk especially in patients who are high risk at baseline. Vascular surgeons and interventionists are ethically bound to ensure all effective alternatives to treatment are explored before patients are exposed to risks of surgery or intervention. The value of medical management compared with surgery or intervention is currently being evaluated in a randomized trial; however, compliance and polypharmacy in the elderly remain real threats to true optimal medical therapy in real practice. In addition to the use of statins and traditional antiplatelet medications, phosphodiesterase-3 inhibitors such as cilostazol have been associated with favorable outcomes for the treatment of ISR in the coronaries and lower extremities as well as the prevention of ISR in a limited number of patients with de novo carotid disease. [37] [38] [39] The mechanism for ISR is primarily myointimal hyperplasia, and the potential benefit of phosphodiesterase-3 inhibition on smooth muscle cell growth deserves full attention and evaluation within the context of carotid restenosis. Effective medical therapy might be most beneficial for patients who progress to occlusion despite multiple attempts at revascularization. We acknowledge that this study is limited in its retrospective design and the duration of follow-up. The similarities between the treatment groups at baseline and over time as shown in Tables I and II, in addition to the modelling techniques for risk adjustment that we have applied, minimize the impact of selection bias on these results. The VQI data does not contain records of the duration between the primary CAS and secondary procedure (redo-CAS or CEA). Hence, we are unable to evaluate the impact of early or late restenosis on these outcomes. In assessing preoperative degree of stenosis, the VQI uses the highest degree of stenosis reported from duplex, magnetic resonance angiogram, computed tomography angiogram, or angiogram, thus, creating a potential for differences in assessment and reporting for degree of stenosis across the multiple centers that contribute to VQI. It is also possible that some of the preceding carotid stents were placed for the treatment of restenosis after CEA, thus, making the index comparison one of a tertiary procedure. We are also unable to ascertain the causes of death and transient or persistent nature of cranial nerve injury. This study contains data up to 1 year. As such our findings might not be generalizable beyond that time point. The relatively small sample of patients in some of the subgroups analyzed in this study attracts wide CIs. These leave room for further study in a larger sample of patients with more complete follow-up. Despite these limitations, this study is novel in its evaluation of contemporary outcomes in an understudied cohort of patients who underwent redo-CAS or CEA after prior CAS.
CONCLUSIONS
In this study, we have reported adverse event rates for CEA and CAS after prior CAS and shown no significant difference in perioperative and 1-year outcomes between both groups. However, CEA is offered to patients who are more severely ill than redo-CAS, resulting in significantly higher absolute mortality. We recommend avoidance of CEA especially in asymptomatic patients with serious systemic disease. Tight management of diabetes and
